Sepracor Plans April 4 Lunesta Launch

Sepracor will launch the insomnia agent upon same-day publication of the final rule designating Lunesta as a Schedule IV controlled substance. More than 40,000 retail pharmacies already have placed orders for eszopiclone, the company says.